石杉碱甲治疗阿尔茨海默病的临床研究现状  

Clinical research status of huperzine A for the treatment of Alzheimer disease

作　　者：王怀荟[1,2] 刘万卉[1,2] 孙雯 

机构地区：[1]烟台大学药学院,烟台264005 [2]山东绿叶制药有限公司,烟台264003

出　　处：《中国新药杂志》2011年第11期993-998,共6页Chinese Journal of New Drugs

摘　　要：石杉碱甲是从草药千层塔中分离得到的一种石松类生物碱,作为乙酰胆碱酯酶抑制剂治疗阿尔茨海默病、血管性痴呆、良性记忆障碍等已有超过16年的临床应用经验。本文检索了公开发表的石杉碱甲治疗阿尔茨海默病的临床研究文献,对于疗程不短于12周的研究按随机安慰剂对照试验、随机阳性药对照试验及协同给药试验分类进行了汇总分析,综述了石杉碱甲治疗阿尔茨海默病的疗效和安全性,同时指出了目前石杉碱甲治疗阿尔茨海默病的研究文献中存在的问题,包括试验疗程偏短、样本量偏小、阳性对照药选择代表性不强等,并对未来的工作提出了建议和展望。Huperzine A is a new lye versible cholinesterase （ACHE） inhibitor, it opod has ium alkaloid isolated from Chinese herb Huperzia serrate. As a rebeen used for the treatment of Alzheimer＇s disease, vascular dementia, benign memory disorders etc. for more than sixteen years. In this review, we searched all the published clinical trials with treatment period no less than 12 weeks and sorted them by randomized placebo-controlled trials, randomized positive controlled trials and combination treatment trials of huperzine A for the treatment of Alzheimer＇s disease. After systematic review, we summarized the efficacy and safety of huperzine A for the treatment of Alzheimer＇s disease, and also raised the problems in these published trials, including short trial courses, few trial samples and the lack of representativeness of positive controls. Some suggestions and perspectives for clinical trials of huperzine A in the treatment of Alzheimer＇s disease were also proposed in this review. future

关 键 词：石杉碱甲 乙酰胆碱酯酶抑制剂 阿尔茨海默病 临床研究 

分 类 号：R971.91[医药卫生—药品]